New Insights Reveal How Leukemia Leverages Lipid Uptake Pathways to Evade CAR-T Therapy

Research study background

B-cell acute lymphoblastic leukemia (B‑ALL) is the most common childhood cancer, with relapse remaining the leading cause of cancer‑related mortality in children. B-ALL cases harboring a TP53 mutation represent one of the most treatment resistant forms of childhood and young adult leukemia. Although a treatment called chimeric antigen receptor-T (CAR-T) cell therapy transformed outcomes for many patients with B-ALL, those with TP53 mutations still experience poor responses or early relapse. The biological basis for this resistance is unclear, prompting efforts to identify how leukemia cells evade CAR‑T cell therapy.

CRISPR is a powerful gene-editing tool that allows scientists to precisely change or switch off genes to study how they work. In a recent study, led by cancer biologist Matthew Witkowski, PhD; pediatric oncologist Kaylyn Lyons, MD; and PhD student Clarissa Garcia, the team worked to use this approach across multiple B‑ALL models to uncover fatty acid transport protein 2 (FATP2) as a potential driver of CAR‑T cell therapy resistance in TP53‑mutant B-ALL.

They found that FATP2 enables leukemia cells to import long‑chain fatty acids and channel them into fatty acid oxidation — where they break down fats for energy — creating a metabolic survival pathway during CAR‑T cell attack. In the study, when FATP2 was deleted — or when lipid uptake or fatty acid oxidation were blocked — TP53‑mutant leukemia cells became more sensitive to CAR‑T cell therapy.

Together, the data reveal that TP53‑mutant leukemia leverages a distinct metabolic program to evade immune‑based therapies. These leukemia cells harness energy from their environment through FATP2-mediated lipid metabolism, giving them a powerful survival advantage under CAR-T cell therapy pressure.

Relevance to future research

This work opens up a new avenue for leukemia research by identifying FATP2‑driven lipid dependence as a targetable metabolic vulnerability in resistant disease. The study suggests that future efforts should refine combination strategies with CAR‑T cell therapy and determine whether blocking lipid uptake or fatty acid oxidation can improve outcomes for patients with high‑risk TP53‑mutant B‑ALL.

“Pediatric leukemia research is important because kids shouldn't die from things that we can stop them from dying from,” Dr. Witkowski says. “Our study just adds another piece of information to the work of our wider research community that may one day lead to something bigger and better for kids.”